

#### UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION 1	VO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/831,253		06/27/2001	Ignacio Jose Ezquerro Saenz	U013446-9	2595
140	7590	09/20/2004	КЗ		AMINER
LADAS & PARRY 26 WEST 61ST STREET				SCHWADRON, RONALD B	
NEW YORK, NY 10023				ART UNIT	PAPER NUMBER
				1644	
				DATE MAILED: 09/20/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.



### **UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	--	---------------------

EXAMINER

ART UNIT PAPER

200409

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

#### **Commissioner for Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

The Office communication mailed 8/25/2003 stated:

The sequence listing filed 5/29/2003 contains the following errors. Section <160> should be 179. The sequence in SEQ. ID. No. 3 is derived from rat type 111 receptor, not human (see Table 5). A new CRF and sequence listing in paper copy are required.

Said errors have not been corrected in the CRF and paper copy of the sequence listing filed 6/23/2004.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Ron Schwadron, Ph.D. Primary Examiner Art Unit 1644 571 272 0851

HONALD B. SCHWADRON
PRIMARY EXAMINER

GROUP 1860 (600)

# Application No. 09/831253 Ezquerro Saewz et al. Notice to Comply Examiner Ron Schwadron, Ph.D. Applicant(s) Ezquerro Saewz et al. 1644 Ph.D.

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

DISCLOSURES
Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: see enclosed communication
Applicant Must Provide:  An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
$oxed{\boxtimes}$ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
$\boxtimes$ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (703) 308-4216 or (703) 308-2923 For CRF Submission Help, call (703) 308-4212 or 308-2923 PatentIn Software Program Support
Technical Assistance703-287-0200

To Purchase Patentin Software.....703-287-0200

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY